Indian Pharma

As technological advancements like AI, machine learning and precision medicine revolutionise drug discovery, manufacturing and patient care, Indian pharmaceutical industry is set for a 'profound transformation' in 2025 with innovation, wider global access and improvement in quality becoming key themes for the future. The industry, which is expected to grow nearly two-fold to around USD 130 billion in size by 2030, is looking to take advantage of conducive policies, demographic and digital talent, in making India play a pivotal role in advancing global health for all. Currently accounting for around 20 per cent of the overall generic drug sales globally, the Indian pharma industry is focussing on research excellence and innovation in order to position the country as a global hub for high-quality, affordable pharmaceuticals. "The Indian pharma market is expected to move up to USD 120-130 billion by 2030 from the current size of USD 58 billion. Initiatives in terms of quality, innovati

He stated that the Indian meditech industry also exported more than the country imported in the surgical and consumable space

Every year on September 25, 2023, World Pharmacist Day is observed as a special day to honour and acknowledge pharmacists for their enormous contributions to enhancing world health

The upcoming budget would be Modi's first major policy announcement in his third term as prime minister

Novo has not provided a clear timeline for introducing Wegovy globally, but told Reuters it aims to launch in India in 2026

Indian drug firms sense opportunity to increase presence in $8.9 bn Saudi market

Jan Aushadhi and trade generics together constitute 20-22% of pharma market volumes

The US health regulator has pulled up Intas Pharmaceuticals for manufacturing lapses, including violation of current good manufacturing practice (CGMP) regulation, at its Ahmedabad-based plant. In a warning letter to the company's CEO and MD Nimish Chudgar, the US Food and Drug Administration (USFDA) has pointed out various manufacturing lapses at the Matoda-Sanand, Ahmedabad-based facility. A warning letter is issued when the US health regulator finds that a manufacturer has significantly violated its regulations. The USFDA inspected the facility from May 1-12, 2023. "This warning letter summarises significant violations of CGMP regulations for finished pharmaceuticals... Because your methods, facilities, or controls for manufacturing, processing, packing, or holding do not conform to CGMP, your drug products are adulterated," it noted. In the warning letter, the health regulator pointed out the company "failed to exercise its responsibility to ensure drug products manufactured

The report underlines the need for collaboration and alignment between the industry, academia and government to advance research and innovation capabilities

Lupin Vilfuro-G is the only FDC that uniquely combines Vilanterol, Fluticasone Furoate, and Glycopyrronium Bromide for the long-term management and treatment of moderate to severe COPD

Acrotech Biopharma is preparing to commercialise Ryzneuta in the United States in the near future

When both our trading partners and our own doctors raise questions about the quality of medicines we make, what is the government doing to assuage these valid concerns?

The delayed season not only affected anti-infectives but also related sub-therapies such as respiratory, cough and cold, gastro, and vitamins, says Juneja

Industry players present at the event highlighted that the OTC market offers a major business opportunity, but it needs transparent and clear regulations

Under the agreement's terms, Biocon will be responsible for obtaining regulatory approvals for Liraglutide and will subsequently manage the manufacturing and distribution of the product within Canada

The newly unveiled manufacturing facility in Pune will produce bioprocessing equipment, including tangential flow, virus filtration, and inactivation systems

Indian pharma exports to Iran have declined from $205.1 million in FY20 to $59.14 million in FY23. Iran's rupee reserves have depleted as India ceased oil imports from the country in mid-2019

The inspection was a routine current Good Manufacturing Practices (cGMP) inspection and a Pre-Approval Inspection (PAI) for a site transfer product within InvaGen

Companies must start preparing their business models to adjust to the reality of the shift to medical practitioners prescribing only generic molecule names

The competitive intensity is high between brands, at a time when volume growth in the domestic pharma market is on a slow lane